SCHEMBL25970052

SCHEMBL25970052

CN(C)c1nc(=O)c(-c2ccccc2)c2ccccn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 1/20 0.41
▸ ALDH1A1 P00352 5/20 0.38
▸ KMT2A Q03164 5/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ PTGS2 P35354 1/20 0.36
▸ RAD51 Q06609 1/20 0.36
▸ HPGD P15428 4/20 0.35
▸ GAA P10253 4/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ POLB P06746 3/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ BAZ2B Q9UIF8 1/20 0.35
▸ BAZ2A Q9UIF9 1/20 0.35
▸ PABPC1 P11940 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ NR2E3 Q9Y5X4 1/20 0.35
▸ NCOR2 Q9Y618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11218668 0.65 BRD4 (0.48) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL25534613 0.63 PTGS2 (0.41) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL28115592 0.62 HTT (0.50) ALDH1A1KMT2AMEN1MAPTPTGS2
SCHEMBL28413218 0.62 PTGS2 (0.41) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL9098561 0.62 PTGS2 (0.51) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL24109558 0.61 MAT2A (0.45) MAT2AALDH1A1KMT2AKDM4EMEN1
SCHEMBL13325875 0.60 PTPN1 (0.55) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL27333922 0.60 ALDH1A1 (0.49) ALDH1A1KMT2AKDM4EMEN1MAPT
SCHEMBL24110100 0.60 MAT2A (0.69) MAT2AALDH1A1MAPK1
SCHEMBL15286911 0.59 NPC1 (0.58) ALDH1A1KDM4EMAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257377-A1 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257377-A1 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2A, MAT2B, MAT1A MAT2A 1/4885ALDH1A1 776/4885KMT2A 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback